| dbo:abstract
|
- Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating high blood uric acid levels associated with gout. It is only recommended together with either allopurinol or febuxostat when these medications are not sufficient. It received FDA approval on 22 December 2015. The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016. In February 2019, it was discontinued in the United States by its manufacturer for business reasons, and was subsequently withdrawn in Europe in July 2020. (en)
- Le lésinurad est une molécule inhibitrice de l' et utilisé comme médicament, en association avec l'allopurinol, dans le traitement de l'hyperuricémie. (fr)
- Lesinurad (nome comercial Zurampic) é um inibidor da reabsorção do ácido úrico usado no tratamento da hiperuricémia associada à gota. Foi aprovado pela FDA em dezembro de 2015. No mesmo mês teve parecer positivo da EMA tendo vindo a ser autorizado em fevereiro de 2016. (pt)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:medlinePlus
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 10275 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:bioavailability
| |
| dbp:br
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:image
|
- Lesinurad ball-and-stick model.png (en)
|
| dbp:iupacName
| |
| dbp:kegg
| |
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:medlineplus
| |
| dbp:metabolism
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pronounce
| |
| dbp:proteinBound
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- FGQFOYHRJSUHMR-UHFFFAOYSA-N (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating high blood uric acid levels associated with gout. It is only recommended together with either allopurinol or febuxostat when these medications are not sufficient. It received FDA approval on 22 December 2015. The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016. In February 2019, it was discontinued in the United States by its manufacturer for business reasons, and was subsequently withdrawn in Europe in July 2020. (en)
- Le lésinurad est une molécule inhibitrice de l' et utilisé comme médicament, en association avec l'allopurinol, dans le traitement de l'hyperuricémie. (fr)
- Lesinurad (nome comercial Zurampic) é um inibidor da reabsorção do ácido úrico usado no tratamento da hiperuricémia associada à gota. Foi aprovado pela FDA em dezembro de 2015. No mesmo mês teve parecer positivo da EMA tendo vindo a ser autorizado em fevereiro de 2016. (pt)
|
| rdfs:label
|
- Lesinurad (fr)
- Lesinurad (en)
- Lesinurad (pt)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
